Oger J - Search Results

1

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V. Goodin DS, et al. Among authors: oger j. Neurology. 2012 Apr 24;78(17):1315-22. doi: 10.1212/WNL.0b013e3182535cf6. Epub 2012 Apr 11. Neurology. 2012. PMID: 22496198 Free PMC article. Clinical Trial.

2

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.

Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T; MAESTRO-01 Investigators. Freedman MS, et al. Among authors: oger j. Neurology. 2011 Oct 18;77(16):1551-60. doi: 10.1212/WNL.0b013e318233b240. Epub 2011 Oct 5. Neurology. 2011. PMID: 21975206 Clinical Trial.

3

Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study.

Shirani A, Zhao Y, Karim ME, Petkau J, Gustafson P, Evans C, Kingwell E, van der Kop ML, Oger J, Tremlett H. Shirani A, et al. Among authors: oger j. Eur J Neurol. 2014 Jun;21(6):835-44. doi: 10.1111/ene.12324. Epub 2013 Dec 18. Eur J Neurol. 2014. PMID: 24351059

4

Beta-interferon exposure and onset of secondary progressive multiple sclerosis.

Zhang T, Shirani A, Zhao Y, Karim ME, Gustafson P, Petkau J, Evans C, Kingwell E, van der Kop M, Zhu F, Oger J, Tremlett H; BC MS Clinic Neurologists. Zhang T, et al. Among authors: oger j. Eur J Neurol. 2015 Jun;22(6):990-1000. doi: 10.1111/ene.12698. Epub 2015 Apr 6. Eur J Neurol. 2015. PMID: 25846809 Free PMC article.

5

Liver test abnormalities in multiple sclerosis: findings from placebo-treated patients.

Tremlett H, Seemüller S, Zhao Y, Yoshida EM, Oger JD, Petkau J. Tremlett H, et al. Among authors: oger jd. Neurology. 2006 Oct 10;67(7):1291-3. doi: 10.1212/01.wnl.0000238515.27055.62. Neurology. 2006. PMID: 17030771 Clinical Trial.

6

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.

Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L. Kappos L, et al. Among authors: oger j. Nat Med. 2000 Oct;6(10):1176-82. doi: 10.1038/80525. Nat Med. 2000. PMID: 11017151 Clinical Trial.

7

Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis.

Schwehr NA, Kuntz KM, Enns EA, Shippee ND, Kingwell E, Tremlett H, Carpenter AF, Butler M; BeAMS Study group. Schwehr NA, et al. Drugs Aging. 2020 Mar;37(3):225-235. doi: 10.1007/s40266-019-00741-1. Drugs Aging. 2020. PMID: 31916231 Free PMC article.

8

Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years.

MacMillan EL, Tam R, Zhao Y, Vavasour IM, Li DK, Oger J, Freedman MS, Kolind SH, Traboulsee AL. MacMillan EL, et al. Among authors: oger j. Mult Scler. 2016 Jan;22(1):112-6. doi: 10.1177/1352458515586086. Epub 2015 May 26. Mult Scler. 2016. PMID: 26014604

9

Autosomal dominant cerebrovascular amyloidosis: properties of peripheral blood lymphocytes.

Stefansson K, Antel JP, Oger J, Burns J, Noronha AB, Roos RP, Arnason BG, Gudmundsson G. Stefansson K, et al. Among authors: oger j. Ann Neurol. 1980 May;7(5):436-40. doi: 10.1002/ana.410070508. Ann Neurol. 1980. PMID: 7396423

10

Immunology of multiple sclerosis.

Oger J, Roos R, Antel JP. Oger J, et al. Neurol Clin. 1983 Aug;1(3):655-79. Neurol Clin. 1983. PMID: 6209537

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

251 results

Search Page

Filters